Combination therapy of tetracyclic quinolone analogs for treating cancer
The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula I or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, wherein A, Q, n, m, R 7 , R 8 , V, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 are as defined herein, and at least one therapeutically active agents selected from immunotherapeutics, anticancer agents, and anti-angiogenics.
1 . A pharmaceutical combination comprising a therapeutically effective amount of Compound A:
or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof; and at least one PARP inhibitor, wherein the PARP inhibitor is Olaparib or talazoparib.
2 . The pharmaceutical combination of claim 1 , wherein the combination is for use in treating breast cancer, colon cancer, or prostate cancer.
3 . The pharmaceutical combination of claim 1 , wherein Compound A and the at least one PARP inhibitor are in separate dosage forms.
4 . The pharmaceutical combination of claim 3 , wherein the separate dosage forms are administered via same mode of administration or different modes of administration.
5 . The pharmaceutical combination of claim 1 , wherein the compound is Compound A:
or a pharmaceutically acceptable salt thereof.
6 . The pharmaceutical combination of claim 1 , wherein the PARP inhibitor is Olaparib.
7 . The pharmaceutical combination of claim 1 , wherein the PARP inhibitor is talazoparib.
8 . The pharmaceutical combination of claim 4 , wherein the separate dosage forms are co-administered via simultaneous administration, sequential administration, overlapping administration, interval administration, continuous administration, or a combination thereof.
9 . The pharmaceutical combination of claim 1 , wherein Compound A is present in an amount from about 1 mg to about 500 mg.